Regulus Therapeutics’ (RGLS) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a research note released on Friday,Benzinga reports. The brokerage currently has a $10.00 price objective on the biopharmaceutical company’s stock. Regulus Therapeutics Price Performance RGLS opened at $1.48 on Friday. Regulus Therapeutics has a 1 year low of $0.83 […]
HC Wainwright reiterated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a research note released on Friday,Benzinga reports. The brokerage currently has a $10.00 price objective on the biopharmaceutical company’s stock. Regulus Therapeutics Price Performance RGLS opened at $1.48 on Friday. Regulus Therapeutics has a 1 year low of $0.83 […]
